Romosozumab (brand name Evenity, Amgen/UCB) is a humanized monoclonal antibody targeting sclerostin, a protein secreted by osteocytes that inhibits the Wnt signaling pathway in osteoblasts. By neutralizing sclerostin, romosozumab simultaneously…